~~What is c~~Claim~~ed i~~s:

1. A method of preparing an antibody pharmaceutical formulation having a viscosity of 10 cP or less comprising during an ultrafiltration/diafiltration step buffer exchanging a composition comprising the antibody with a diafiltration buffer comprising at least 20 mM calcium acetate ~~salt~~ at a temperature greater than 30°C.

~~2. The method of claim 1, wherein the exchanging step occurs via ultrafiltration/diafiltration.~~

~~3~~2. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 90 mg/mL.

3~~4~~. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 120 mg/mL.

4~~5~~. The method of any one of claims 1-3~~4~~, wherein the exchanging step occurs at a temperature between 30°C and 40°C.

5~~6~~. The method of any one of claims 1-4~~5~~, wherein the exchanging step occurs at a temperature greater than 35°C.

6~~7~~. The method of any one of claims 1-5~~6~~, wherein the exchanging step occurs at 37°C.

~~8. The method of claim 1, wherein the calcium salt is calcium acetate.~~

~~9. The method of claim , wherein the diafiltration buffer comprises least 20 mM calcium acetate.~~

~~10~~7. The method of claim 9, wherein the diafiltration buffer comprises ~~about~~ 23 mM calcium acetate.

8~~11~~. The method of any one of claims 1-7~~10~~, wherein the diafiltration buffer further comprises a polyol.

9~~12~~. The method of claim ~~11~~8, wherein the polyol is sucrose.

1~~3~~0. The method of claim 9~~12~~, wherein diafiltration buffer comprises sucrose present at a concentration of ~~about~~ 1% to ~~about~~ 15%.

141. The method of claim 912, wherein the diafiltration buffer comprises sucrose at a concentration of about 7%.

152. The method of any one of claims 1-114, further comprising the step of filtering the pharmaceutical formulation.

163. The method of any one of claims 1-142, further comprising the step of aliquoting the pharmaceutical formulation into a drug product form.

174. The method of any one of claims 1-163, wherein the antibody is romosozumab, abciximab, adalimumab, alemtuzumab, basiliximab, belimumab, bevacizumab, brentuximab vedotin, canakinumab, cetuximab, certolizumab pegol, daclizumab, denosumab, eculizumab, efalizumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, nivolumab, ofatumumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tocilizumab, tositumomab, trastuzumab or ustekinumab, vedolizumab.

185. The method of any one of claims 1-174, wherein the pharmaceutical formulation after the exchanging step comprises at least ~~about~~ 50 mM acetate and ~~about~~ 12 mM calcium.